GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nu-Med Plus Inc (OTCPK:NUMD) » Definitions » EPS (Diluted)

NUMD (Nu-Med Plus) EPS (Diluted) : $-0.00 (TTM As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Nu-Med Plus EPS (Diluted)?

Nu-Med Plus's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was $0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.00.

Nu-Med Plus's EPS (Basic) for the three months ended in Sep. 2024 was $0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.00.

Nu-Med Plus's EPS without NRI for the three months ended in Sep. 2024 was $0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.00.

During the past 3 years, the average EPS without NRIGrowth Rate was 63.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 46.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 16.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Nu-Med Plus's highest 3-Year average EPS without NRI Growth Rate was 63.20% per year. The lowest was -78.80% per year. And the median was -4.90% per year.


Nu-Med Plus EPS (Diluted) Historical Data

The historical data trend for Nu-Med Plus's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nu-Med Plus EPS (Diluted) Chart

Nu-Med Plus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -0.04 -0.01 - -

Nu-Med Plus Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nu-Med Plus's EPS (Diluted)

For the Medical Devices subindustry, Nu-Med Plus's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nu-Med Plus's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nu-Med Plus's PE Ratio distribution charts can be found below:

* The bar in red indicates where Nu-Med Plus's PE Ratio falls into.



Nu-Med Plus EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Nu-Med Plus's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-0.126-0)/81.674
=-0.00

Nu-Med Plus's Diluted EPS for the quarter that ended in Sep. 2024 is calculated as

Diluted EPS (Q: Sep. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-0.019-0)/81.348
=-0.00

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nu-Med Plus  (OTCPK:NUMD) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Nu-Med Plus EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Nu-Med Plus's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Nu-Med Plus Business Description

Traded in Other Exchanges
N/A
Address
640 Belle Terre Road, Building 2 E Port, Jefferson, NY, USA, 11777
Nu-Med Plus Inc is an medical device company principally engaged in the design, innovation, development, enhancement, and commercialization of beginning, early, and selective later-stage quality medical devices. It focuses on the formulation of Nitric Oxide powder, which is a desktop generator device which delivers inhaled Nitric Oxide to replace expensive pressurized canisters and a mobile rechargeable device to deliver inhaled Nitric Oxide gas to offer solutions to hospitals, health systems and medical community throughout the world.
Executives
William C Hayde director, officer: CEO 76 CLIFF ROAD, BELLE TERRE NY 11777
Wendy P. Smith 10 percent owner P. O. BOX 1374, SALT LAKE CITY UT 84110
Brett J. Earl director, officer: VP of Medical Marketing P.O. BOX 729, MORGAN UT 84050
Mark Edward Christensen officer: CFO, Sec, Treas, Prin Acct Off 455 E. 500 S., SUITE 207, SALT LAKE CITY UT 84111
Thomas A Tait 10 percent owner 514 AMERICAS WAY #5556, BOX ELDER SD 57719
Craig Morrison director, 10 percent owner, officer: Vice President of Technology 975 NORTH TERRACE DRIVE, PROVO UT 84604
William G Moon director, 10 percent owner, officer: Vice President of Operations 1266 SOUTH 1380 WEST, OREM UT 84058
Jeffrey Lynn Robins director, 10 percent owner, officer: CEO 455 EAST 500 SOUTH, SUITE #205, SALT LAKE CITY UT 84111